GEOVAX LABS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $4.0M | $0 | $81.5K | $385.5K | $1.8M | $1.2M | $963.2K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $18.1M | $23.7M | $20.7M | $9.1M | $15.6M | $2.4M | $1.9M | $1.9M |
| SG&A Expense | $6.0M | $5.4M | $6.0M | $5.0M | $3.6M | $2.2M | $1.6M | $1.6M |
| Operating Income | $-21.6M | $-25.1M | $-26.7M | $-14.0M | $-18.7M | $-2.8M | $-2.4M | $-2.6M |
| Operating Margin | -869.3% | -635.8% | — | -17,207.5% | -4,862.7% | -154.5% | -201.8% | -266.1% |
| Interest Expense | — | — | — | $0 | $1.3K | $143.5K | $4.5K | $2.6K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | $0 | $0 | $0 | $0 |
| Net Income | $-21.5M | $-25.0M | $-26.0M | $-14.0M | $-18.6M | $-3.0M | $-2.4M | $-2.6M |
| Net Margin | -862.3% | -632.0% | — | -17,198.3% | -4,817.2% | -162.2% | -201.6% | -265.8% |
| EPS (Basic) | $-22.40 | $-24.09 | $-2.86 | $-2.48 | $-0.61 | $-0.43 | $-156.37 | $-3,122.07 |
| EPS (Diluted) | — | — | — | — | $-0.61 | $-0.43 | $-156.37 | $-3,122.07 |
| Shares Outstanding (Basic) | 958.4K | 1.0M | 9.1M | 5.7M | 30.5M | 19.2M | 75.0K | 1.09B |
| Shares Outstanding (Diluted) | 958.4K | 1.0M | 9.1M | 5.7M | 30.5M | 19.2M | 75.0K | 1.09B |
| Dividends Per Share | — | — | — | — | — | — | — | — |